Hormonal contraceptive choice for women with PCOS: A systematic review of randomized trials and observational studies

Gynecological Endocrinology

Volumn 30, Issue 12, 2014, Pages 850-860

  Mendoza, Nicolas ^a   Simoncini, Tommaso ^b   Genazzani, Alessandro D ^c  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Hirsutism; Hormonal contraception; Ovary; Polycystic ovary syndrome

Indexed keywords

CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; CONTRACEPTIVE AGENT; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIENOGEST PLUS ESTRADIOL VALERATE; DROSPIRENONE PLUS ETHINYLESTRADIOL; METFORMIN; ORAL CONTRACEPTIVE AGENT;

ARTICLE; CARBOHYDRATE METABOLISM; CARDIOMETABOLIC RISK; DRUG PREFERENCE; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; META ANALYSIS; MONOTHERAPY; OBESITY; OBSERVATIONAL STUDY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; SYSTEMATIC REVIEW; VAGINA RING; COMPLICATION; DECISION MAKING; POLYCYSTIC OVARY SYNDROME;

CONTRACEPTIVES, ORAL, HORMONAL; DECISION MAKING; FEMALE; HUMANS; HYPERANDROGENISM; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84910605347     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2014.943725     Document Type: Article

References (62)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003, consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Human Reprod 2004;19:41-7.
2. de Groot PC, Dekkers OM, Romijn JA, et al. PCOS, coronary heart disease, stroke and the influence of obesity: A systematic review and meta-Analysis. Hum Reprod Update 2011;17:495-500.
3. Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 2005;11: 277-91.
4. Bird ST, Hartzema AG, Brophy JM, et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: A population-based matched cohort analysis. CMAJ 2013;185: E115-20.
5. Prisma. The Prisma Statement. Available at: Http://www.prismastatement. org/statement.htm.
6. Battaglia C, Mancini F, Fabbri R, et al. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenoneethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. Fertil Steril 2010;94:1417-25.
7. Kriplani A, Periyasamy AJ, Agarwal N, et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2010;82: 139-46.
8. De Leo V, Di Sabatino A, Musacchio MC, et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception 2010;82: 276-80.
9. Harris-Glocker M, Davidson K, Kochman L, et al. Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. Fertil Steril 2010; 93:1016-19.
10. Oner G, Muderris II. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism. Contraception 2011; 84: 508-11.
11. Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenona in patients with polycystic ovary syndrome. Fertil Steril 2012;98:1053-9.
12. Colonna L, Pacifico V, Lello S, et al. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: Clinical and instrumental evaluation. J Eur Acad Dermatol Venereol 2012;26:1364-71.
13. Karakurt F, Sahin I, Guler S, et al. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/ cyproterone acetate in the treatment of hirsutism: A randomized controlled study. Adv Ther 2008;25:321-8.
14. Hadziomerovic-Pekic D, Wildt L, Weiss JM, et al. Metformin, naltrexone, or the combination of prednisolone and antiandrogenic oral contraceptives as first-line therapy in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril 2010;94:2385-8.
15. Panidis D, Georgopoulos NA, Piouka A, et al. The impact of oral contraceptives and metformin on anti-Mullerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol 2011;27:587-92.
16. Romualdi D, De Cicco S, Busacca M, et al. Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: A randomized study. J Endocrinol Invest 2013;36:636-41.
17. Luque-Ramirez M, Alvarez-Blasco F, Uriol Rivera MG, Escobar-Morreale HF. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: Effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Hum Reprod 2008;23:1594-601.
18. Luque-Ramirez M, Mendieta-Azcona C, del Rey Sanchez JM, et al. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: Influence of obesity and smoking. Eur J Endocrinol 2009;160:469-80.
19. Moran LJ, Meyer C, Hutchison SK, et al. Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention. J Endocrinol Invest 2010;33:258-65.
20. Kebapcilar L, Taner CE, Kebapcilar AG, et al. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Arch Gynecol Obstet 2010;281:35-42.
21. Essah PA, Arrowood JA, Cheang KI, et al. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertil Steril 2011;96:501-4.
22. Orbetzova MM, Pehlivanov BK, Mitkov MM, et al. Effect of shortterm standard therapeutic regimens on neuropeptide Y and adipose tissue hormones in overweight insulin-resistant women with polycystic ovary syndrome. Folia Med (Plovdiv) 2011;53:15-24.
23. Kilic S, Yilmaz N, Zulfikaroglu E, et al. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecol Endocrinol 2011;27:622-9.
24. Vieira CS, Martins WP, Fernandes JB, et al. The effects of 2mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception 2012;86:268-75.
25. Uras R, Orru M, Pani F, et al. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome. Contraception 2010;82: 131-8.
26. Minozzi M, Costantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol 2011;27:920-4.
27. Banaszewska B, Spaczynski RZ, Ozegowska K, Pawelczyk L. [The influence of low-dose oral contraceptive pill on clinical and metabolic parameters in young women with polycystic ovary syndrome]. Ginekol Pol 2011;82:430-5.
28. Gomes VA, Vieira CS, Jacob-Ferreira AL, et al. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome. Basic Clin Pharmacol Toxicol 2012;111:211-16.
29. Aydin K, Cinar N, Aksoy DY, et al. Body composition in lean women with polycystic ovary syndrome: Effect of ethinyl estradiol and drospirenone combination. Contraception 2013;87:358-62.
30. De Leo V, Fruzzetti F, Musacchio MC, et al. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception 2013;88:364-8.
31. Cinar N, Harmanci A, Bayraktar M, Yildiz BO. Ethinyl estradioldrospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2013;78:379-84.
32. Harmanci A, Cinar N, Bayraktar M, Yildiz BO. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2013;78:120-5.
33. Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010;94:2197-201.
34. Rehme MF, Pontes AG, Goldberg TB, et al. Manifestacoes clinicas, bioquimicas, ultrassonograficas e metabolicas da sindrome dos ovarios policisticos em adolescentes [Clinical manifestations, biochemical, ultrasonographic and metabolic of polycystic ovary syndrome in adolescents]. Rev Bras Ginecol Obstet 2013;35: 249-54.
35. Brown ZA, Louwers YV, Fong SL, et al. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil Steril 2011;96:1259-65.
36. Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: Association of polycystic ovary syndrome with metabolic syndrome and non-Alcoholic fatty liver disease. Aliment Pharmacol Ther 2011;33:801-14.
37. Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 2010;122:42-52.
38. Toulis KA, Goulis DG, Mintziori G, et al. Meta-Analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17:741-60.
39. de Groot PC, Dekkers OM, Romijn JA, et al. PCOS, coronary heart disease, stroke and the influence of obesity: A systematic review and meta-Analysis. Hum Reprod Update 2011;17:495-500.
40. Mendoza N. Common genetic aspects between polycystic ovary syndrome and diabetes mellitus. Curr Diabetes Rev 2011;7:377-91.
41. Toulis KA, Goulis DG, Kolibianakis EM, et al. Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: A systematic review and a meta-Analysis. Fertil Steril 2009;92: 667-77.
42. Palomba S, Falbo A, Russo T, et al. Pregnancy in women with polycystic ovary syndrome: The effect of different phenotypes and features on obstetric and neonatal outcomes. Fertil Steril 2010;94: 1805-11.
43. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011;(7):CD007506.
44. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009;15: 477-88.
45. Moghetti P, Tosi F, Bonin C, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab 2013;98:E628-37.
46. ESHRE CapriWorkshop Group. Health and fertility inWorld Health Organization group 2 anovulatory women. Hum Reprod Update 2012;18:586-99.
47. Dunaif A, Fauser BC. Renaming PCOS-A two-state solution. J Clin Endocrinol Metab 2013;98:4325-8.
48. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565-92.
49. Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 2005;11: 277-91.
50. Bird ST, Hartzema AG, Brophy JM, et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: A population-based matched cohort analysis. CMAJ 2013;185: E115-20.
51. Fruzzetti F, Tremollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: Focus on estradiol valerate/dienogest. Gynecol Endocrinol 2012;28: 400-8.
52. Kallio S, Puurunen J, Ruokonen A, et al. Antimullerian hormone levels decrease in women using combined contraception independently of administration route. Fertil Steril 2013;99:1305-10.
53. Anthuber S, Schramm G, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2mg/ethinylestradiol 0.003mg in young women. Clin Drug Investig 2010;30:211-20.
54. Goretzlehner G, Waldmann-Rex S, Schramm G. Extended cycles with the combined oral contraceptive chlormadinone acetate 2 mg/ ethinylestradiol 0.003 mg. Clin Drug Investig 2011;31:269-77.
55. Sanger N, Stahlberg S, Manthey T, et al. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2mg dienogest on thyroid hormones and androgen parameters: Conventional vs. extended-cycle use. Contraception 2008;77:420-5.
56. Bozdag G, Yildiz BO. Combined oral contraceptives in polycystic ovary syndrome-indications and cautions. Front Horm Res 2013;40: 115-27.
57. Westhoff CL, Torgal AT, Mayeda ER, et al. Predictors of noncompliance in an oral contraceptive clinical trial. Contraception 2012;85:465-9.
58. Halperin IJ, Kumar SS, Stroup DF, Laredo SE. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: A systematic review and meta-Analysis of observational studies. Hum Reprod 2011;26:191-201.
59. Costello MF, Shrestha B, Eden J, et al. Metformin versus oral contraceptive pill in polycystic ovary syndrome: A Cochrane review. Hum Reprod 2007;22:1200-9.
60. Jing Z, Liang-Zhi X, Tai-XiangW, et al. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: An updated systematic review. Gynecol Endocrinol 2008;24:590-600.
61. World Health Organization. Medical eligibility criteria for contraceptive use. 4th ed. Available from: Http://whqlibdoc.who.int/ publications/2010/9789241563888-eng.pdf. 2009.
62. Verhaeghe J. Hormonal contraception in women with the metabolic syndrome: A narrative review. Eur J Contracept Reprod Health Care 2010;15:305-13.